1Neri D Bicknen R. Tumour vascular targeting. Nat Rev Cancer,2005,5 (6) :436 -446.
2Backer MV, Hamby CV, Backer JM. Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature. Adv Genet ,2009,67 : 1 - 27.
3Moser C, Lang SA, Stoehzing O. The direct effects of anti - vascular endothelial growth factor therapy on tumor cells. Clin Colorectal Cancer, 2007,6(8) :564 -571.
4Jain L, Vargo CA, Danesi R, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther,2009,8 ( 9 ) :2496 - 2508.
5Nitzsche B, Gloesenkamp C, Sehrader M, et al. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicu- lar germ cell tumours. Br J Cancer,2010,29;103 (1) :18 -28.
6Saito A, Sugawara A, Uruno A,et al. All - trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signa- ling. Endocrinology ,2007,148 ( 3 ) : 1412 - 1423.
7Zage PE, Zeng L, Palla S,et al. A novel therapeutic combination for neuroblastoma:the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandet- anib with 13 - cis - retinoic acid. Cancer,2010,15,116 ( 10 ) :2465 -2475.
8Folkman J. Antiangiogenic gene therapy [ J ]. Proc Natl Acad Sci USA, 1998, 95 (16) :9064 - 9066.
9Kong HL, Crystal RG. Gene therapy strategies for tumor aatiangiogenesis[J]. Natl Cancer Inst, 1998, 90 (4) :273- 286.
10Cao Y. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments[J]. Prog Mol Subcell Biol, 1998, 20:161-176.
